# Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas

Source: https://onco.cc/trials/nct05768919/  
OnCo record `nct05768919` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Treatment Period 1 in glioma & glioblastoma, run by SignPath Pharma, Inc., now recruiting.

## Summary

Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas is a phase 1/2 interventional study registered as NCT05768919 by SignPath Pharma, Inc., with 30 participants planned, started 2023-03-03 and due to reach its primary completion in 2026-02. Interventions recorded: Treatment Period 1, Treatment Period 2, Treatment Period 3 and Treatment Period 4a.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05768919
- Phase: 1/2
- Setting: Phase I/II Study of the Tolerability, Safety, and Efficacy of Liposomal Curcumin in Combination With Radiation and Temozolomide in Patients With Newly Diagnosed High-Grade Gliomas
- Sponsor: SignPath Pharma, Inc.
- Enrolled: 30

## Sources

- ClinicalTrials.gov NCT05768919: https://clinicaltrials.gov/study/NCT05768919

## Connected records

- cancers: [Glioma & glioblastoma](https://onco.cc/cancers/glioblastoma/)

---
JSON: https://onco.cc/api/v1/entities/nct05768919.json